The U.S. Food and Drug Administration (FDA) has reported positive results in its Phase 2a trial of an oral insulin capsule produced by Israeli-based Oramed. The drug is for the treatment of Type 2 diabetes.
The Phase 2b study will be carried out later this year, and Oramed also plans a Phase 2a study for Type 1 diabetes.
Oramed’s stock jumped nearly 10 percent in NASDAQ trading in New York on Wednesday in after-hours trading following the announcement of the results of the trial.
“We are extremely pleased with the results, which give a solid validation for Oramed’s platform technology in general and our oral insulin program in particular,” said Nadav Kidron, Oramed’s chief executive.